Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MET | P08581 | 20/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3425778 | 0.86 | MET (1.00) | MET | |
| SCHEMBL3426338 | 0.86 | MET (1.00) | MET | |
| SCHEMBL12124598 | 0.85 | MET (0.74) | MET | |
| SCHEMBL1330619 | 0.81 | MET (0.74) | MET | |
| SCHEMBL15288749 | 0.79 | MET (0.65) | MET | |
| SCHEMBL3424282 | 0.78 | MET (1.00) | MET | |
| SCHEMBL16506693 | 0.78 | MET (0.64) | MET | |
| SCHEMBL12489734 | 0.78 | MET (0.64) | MET | |
| SCHEMBL12487198 | 0.78 | MET (0.64) | MET | |
| SCHEMBL2573179 | 0.78 | MET (1.00) | MET |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2247185-B1 | TYROSINE KINASE INHIBITORS | TIGER PHARMATECH (US) | 2014-04-16 | — | — | EP | claimed |
| US-8598184-B2 | Protein kinase inhibitors | TIGER PHARMATECH (US) | 2013-12-03 | — | — | US | claimed |
| US-20100324074-A1 | Protein Kinase Inhibitors | ZHANG JUNHU | 2010-12-23 | — | — | US | claimed |
| EP-2247185-A2 | TYROSINE KINASE INHIBITORS | Tiger Pharmatech (US) | 2010-11-10 | — | — | EP | claimed |
| WO-2009111354-A2 | TYROSINE KINASE INHIBITORS | TIGER PHARMATECH (US) | 2009-09-11 | — | — | WO | claimed |
| EP-2247185-B1 | TYROSINE KINASE INHIBITORS | TIGER PHARMATECH (US) | 2014-04-16 | — | — | EP | disclosed |
| EP-2247185-B1 | TYROSINE KINASE INHIBITORS | TIGER PHARMATECH (US) | 2014-04-16 | — | — | EP | disclosed |
| US-8598184-B2 | Protein kinase inhibitors | TIGER PHARMATECH (US) | 2013-12-03 | — | — | US | disclosed |
| US-20100324074-A1 | Protein Kinase Inhibitors | ZHANG JUNHU | 2010-12-23 | — | — | US | disclosed |
| US-20100324074-A1 | Protein Kinase Inhibitors | ZHANG JUNHU | 2010-12-23 | — | — | US | disclosed |
| US-20100324074-A1 | Protein Kinase Inhibitors | ZHANG JUNHU | 2010-12-23 | — | — | US | disclosed |
| EP-2247185-A2 | TYROSINE KINASE INHIBITORS | Tiger Pharmatech (US) | 2010-11-10 | — | — | EP | disclosed |
| WO-2009111354-A2 | TYROSINE KINASE INHIBITORS | TIGER PHARMATECH (US) | 2009-09-11 | — | — | WO | disclosed |
| WO-2009111354-A2 | TYROSINE KINASE INHIBITORS | TIGER PHARMATECH (US) | 2009-09-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100324074-A1 | Protein Kinase Inhibitors | MET, ABL1, ERBB2 | MET 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.